Slingshot Insights

Catalyst

Slingshot members are tracking this event:

PDUFA Date for F/TAF for Treatment of HIV set for April 7, 2016

Source Link:: http://investors.gilead.com/phoenix.zhtml?c=69964&p=IROL-secToc&TOC=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9vdXRsaW5lLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTA3Njg1MTImc3Vic2lkPTU3&ListAll=1&sXBRL=1

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

GILD

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The PDUFA date for Gilead's is April 7, 2016. If approved, it will join four other single tablet regimens already approved for treatment of HIV developed by Gilead.

http://investors.gil...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Apr 04, 2016

Occurred Source:

http://www.gilead.com/news/press-releases/2016/4/us-food-and-drug-administration-approves-descovy-emtricitabine-tenofovir-alafenamide-gileads-third-tafbased-hiv-therapy

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords F/taf, Emtricitabine, Tenofovir Alafenamide, Hiv, Pdufa